Samsung Biologics will actively seek new CDMO clients at the upcoming Drug, Chemical & Associated Technologies Association (DCAT) Week 2025, set to take place in New York, U.S., from March 17 to 20.
Samsung Biologics will attend DCAT Week 2025 in New York to expand global partnerships, highlight its CDMO capabilities, and strengthen business networks.
Samsung Biologics will attend DCAT Week 2025 in New York to expand global partnerships, highlight its CDMO capabilities, and strengthen business networks.
DCAT Week, which originated in 1890 under the auspices of the New York Chamber of Commerce, is a global networking event for the pharmaceutical and biotechnology industries. Now organized annually by the DCAT Association, the event brings together industry leaders, with over 90 percent of attendees holding key decision-making positions, making it an optimal platform for corporate partnership discussions.
Samsung Biologics has been a consistent participant in DCAT Week since 2016, marking its 10th consecutive appearance this year, except for 2020 when the event was canceled due to the Covid-19 pandemic. At this year’s event, the company will set up a dedicated meeting room in a prime location, where it plans to conduct over 50 business meetings with global pharmaceutical firms over three days.
CEO John Rim will attend in person for the third consecutive year to engage in strategic partnership discussions with key industry figures. Samsung Biologics aims to leverage the event to highlight its competitive edge as a leading contract development and manufacturing organization (CDMO) and drive substantial business expansion through new client acquisitions and contract signings.
As part of its participation, Samsung Biologics will sponsor DCAT Week’s main dinner event on March 20, joining other leading CDMO firms such as Lonza and Thermo Fisher Scientific. The dinner will bring together more than 2,500 industry executives, providing a valuable opportunity to expand networks and strengthen business partnerships.
The company also plans to enhance its brand recognition as a global CDMO leader through on-site promotional materials, including banners and marketing collateral.
In addition to DCAT Week, Samsung Biologics will expand its global engagement by attending major industry conferences, including the Festival of Biologics USA in April in San Diego and the PEGS Boston Summit in May.
Related articles
Samsung Biologics, Bioepis guarantee jobs for bio R&D graduates from Sungkyunkwan, Korea University
Samsung Biologics cleared of criminal liability as court rejects fraud charges
Samsung Biologics achieves record ₩4 tril. revenue in 2024, operating profit up 19%
[JPM 2025] Samsung Biologics aims to strengthen global leadership with expanded capacity and portfolio
Lee Han-soo corea022@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited